Treatment of dilated cardiomyopathy with or without inflammation;Therapie der dilatativen kardiomyopathie mit und ohne entzundung

Medizinische Klinik

Volumn 93, Issue 4, 1998, Pages 240-251

  Hufnagel, Günter ^a,b   Pankuweit, Sabine ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Zentrum Innere Medizin   (Germany)

Author keywords

Dilated cardiomyopathy; Endomyocardial biopsy; ESETCID; Immunomodulation; Immunosuppressive treatment; Myocarditis; Viral persistence

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPERIMMUNE GLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; VASODILATOR AGENT;

ASSISTED CIRCULATION; CONTROLLED STUDY; HEART DILATATION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMOBILIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; PERSISTENT VIRUS INFECTION; PROGNOSIS; REVIEW; SURVIVAL RATE;

ADENOVIRIDAE; CYTOMEGALOVIRUS; DIGITALIS; ENTEROVIRUS;

EID: 0032522792     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044800     Document Type: Review

References (103)

1. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis - a histopathologic definition and classification. Am J Cardiovasc Patho 1986,1;3-14.
2. Bowles NE, Richardson PJ,Olsen E, Archard L. Detection of Coxsackie B virus specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy, Lancet 1986,1:1120-3.
3. Bowles NE, Rose ML, Taylor P, et al. End-stage dilated cardiomyopathy persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989;80 1128-36.
4. Burch GE, Giles TD. Prolonged bed rest in the management of patients with cardiomyopathy. Cardiovasc Clin 1972.4;375-87
5. Camenm F, Salvi A, Bussani R, et il Immunosuppressive treatment in myocarditis In: Schutrheiss HP, ed. New concepts in viral heart disease. Berhn-Heidelberg-New York: Springer, 1988:402-25.
6. Chan KY, Iwahara M, Benson LN, Wilson GJ, Freedom RM. Immunosuppressive therapy in the management of acute myocarditis in children: a clinical trial. J Am Coll Cardiol 1991,17.458-60
7. Chapman NM, Tracy S, Gauntt CJ, Fortmüller U. Molecular detection and identification of enteroviruses using enzymatic amplification and nucleic acid hybridization. J Clin Microbiol 1990;28:843-50
8. Cooper LT, Shabecai R. Immunosuppressive therapy for myocarditis (letter). N EnglJ Med 1995;333:1713-4.
9. Cunmon RE, Panllo JE. Immunosuppressive therapy for myocarditis (letter). N Engl J Med 1995;333:1713
10. Daly K, Richardson PJ, Olsen EG. Acute myocarditis: role of histological and virological examination in the diagnosis of immunosuppressive treatment Br Heart J 1984,51:30-5.
11. Dec WG, Palacios IG, Fallon JT. Southern JF Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med 1985;312:885-90
12. Dorffel WV, Felix SB, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomvopathy Circulation 1997;95:1994-7.
13. Drucker NA. Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994;89.252-7
14. Estrin M, Smith C, Huber SA. Coxsackievirus B3 myocarditis: T-cell autoimmunitiy to heart antigens is resistant to cyclosporin A treatment Am J Pathol 1986; 125 244-51
15. Fenoglio JJ, Ursell PC, Kellog CF, Drusin RE, Weiss MB Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 1983;308:12-8.
16. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996;94-346-52.
17. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine Coxsackievirus B-3 myocardiopathy by exercise J Exp Med 1970;131:1121-36.
18. Giesecke J. The long-term prognosis in acute myocarditis. Eur Heart J 1987;8:Suppl J:251-3.
19. Hahn EA, Hartz VL, Moon TE, et al. for the Myocarditis Treatment Trial Investigators. The Myocarditis Treatment Trial. design. methods and patient enrollment Eur Heart J 1995;16:Suppl O:162-7.
20. Hengstenberg C, Rose ML, Olsen EG, Maisch B, Immune response to the endothelium in myocarditis, dilated cardiomyopathy and rejection after heart transplantation. Eur Heart J 1991;12 Suppl D 144-6
21. Herzum M, Ruppert V, Kuytz B, Jomaa H, Nakamura I, Maisch B Coxsackievirus B3 infection leads to cells death of cardiac myocytes. Mol Cell Cardiol 1994;26: 907-13.
22. Hobbs RE, Pelegrin D, Ratliff NB, et al. Lymphocytic myocarditis and dilated cardiomyopathy. treatment with immunosuppressive agents. Cleve Clin J Med 1989;56: 628-35.
23. Hosenpud JD, McAnulty JH, Niles NR Lack of objective improvement in ventricular function in patients with myocarditis treated with azathioprine and prednisone. J Am Coll Cardiol 1985;6:217-22.
24. Huber SA, Polgar J, Schultheiss H-P, Schwimmbeck P. Augmentation of pathogenesis of coxsackievirus. B3 infection in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 1994;68:195-206.
25. Hufnagel G, Maisch B. Expression of MHC class. I and II antigens and the II-2 receptor m rejection, myocarditis and dilated cardiomyopathy Eur Heart J 1991,12:Suppl D: 137-40
26. Hufnagel G, Busse C, Ische B, Maisch B. Detection of adenoviral DNA in endomyocardial biopsies of adult patients with myocarditis and dilated cardiomyopathy. Eur Heart J 1997, 18:515.
27. Jin O, Sole M, Butany J W, et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cirdiomyopathy using gene amplification by polymerase chain reaction Circulation 1990,82.8-16
28. Jones RS, Herskowitz A, Hutchins MG, Baugham LK, Effects of immunosuppressive therapy in biopsy proven myocarditis and borderline myocarditis in left ventricular function Am J Cardiol 1991;68 370-6.
29. Kandolf R, Ameis D, Kirschner P,Canu A, Hofschneider PH. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987;84:6272-6.
30. Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S. Cytokme and murine coxsackievirus B3 myocarditins: interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 1994;89:2836-42.
31. Klingel K, Hohenadl C, Cann A, et al Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection; quantitative analysis of virus replication, tissue damage and inflammation. Proc Natl Acad Sci USA 1992;89:314-8
32. Kuhl U, Schultheiss H-P. Treatment of chronic myocardits with cortcostcroids. Eur Heart J 1995;16'Suppl O:168-72.
33. Kühl U, Melzner B, Schafer B, Schultheiss H-P, Strauer BE. The Ca-charnnel as cardiac autoanngen Eur Heart J 1991,12-Suppl D.99-104
34. Kuhl U, Daun B, Seeberg B, Schultheiss H-P, Strauer BE Dilated cardiomvopithy: a chronic myocarditis? Immunohistological characterization of lymphocyric mFiltrates. Herz 1992; 17.97-106.
35. Levine HD Virus myocarditis: a critique of the literature from clinical, echocardiographic and pathological stand-poines. Am J Med Sci 1979,277:132-43.
36. Limas CJ, Limas C Beta-adrenoreceptor antibodies and genetics in dilated cardiomyopathy an overview and review, Eur Heart J 1991;12:Suppl D: 175-7.
37. Lyden DC, Feran M. Olszewski J, Job LP, Huber SA Coxsackievirus B3 induced myocarditis: effect of sex steroids on viremia and infccrivity of cardiocytes, Ant J Pathol 1987; 126:432-8
38. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebecke J Automimumty in idiopathic dilated cardiomyopathy, characterization of antibodies against the beta 1-adrenoreceptor with positive chronotropic effect. Circulation 1994;89:2760-7.
39. Maisch B. Immunologic regulator and effector function in perurinyocarditis. postniyocarditic lieart muscle disease and dilated cardiomyopathy Basic Res Cardiol 1986;81.Suppl 1:217-42.
40. Maisch B. Myocardits. Curr Opin Cardiol 1990;5.320-7
41. Maisch B, The sarcolemma as antigen in the secondary immunopathogenesis of myopencarditis. Eur Heart J 1987;8:Suppl J:155-65.
42. Maisch B, Bauer E, Hufnagel G, Peiffer U, Rohkamm R. The use of endomyocardial biopsy in heart failure. Eur Heart J 1988:9-Suppl H:59-71.
43. Maisch B, Bauer E, Cirsi M, Kochsiek K. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance Circulation 1993;87:IV 49-65
44. Maisch B, Camerini F, Schultheiss H-P. Immunosuppressive therapy for myocarditis (letter). N Engl J Med 1995;333:1713.
45. Maisch B, Drude L, Hengstenberg C, Herzum M, Hufnagel G, Schuman LJ Are antisarcok-mmal (ASAs) and antiniyoleminal antibodies (AMLAs) "natural" antibodies? Basic Res Cardiol 1991,86:101-14.
46. Maisch B, Drude L, Hengstenberg C, Herzum M, Hufnagel G, Schönian U. Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis. Postgrad Med J 1992,68-Suppl 1 6-11.
47. Maisch B, Factor S, Grone, et. al. Report of the 1997 The International Society and Federation of Cardiology Expert Committee on the definition of inflammatory cardiomyopathv (chronic myocarditis). Circulation (submitted).
48. Maisch B, Herzum H, Hfnagd G, Schönian U, Immunosuppressive and Immunomodulatory treatment for myocarditis. Curr Opin Cardiol 1996;11:310-24.
49. Maisch B, Herzum M, Hufnagel G, Bethge C, Schönian U. Immunosuppressive treatment for myocarditis and dilated cardiomyopathy Eur Heart J 1995;16:Suppl O: 153-61.
50. Maisch B, Hufnagel G, Schönian U, Hengstenberg C, for the ESETCID investigators. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995;16:Suppl O. 173-5.
51. Maisch B, Lotze U, Schneider J, Kochsiek K Antibodies to human sinus node in sick sinus syndrome Pace 1986;9:1101-12.
52. Maisch B, Weyerer O, Hufnagel G, Hengstenberg C, Schönian U The vascular end-othelium as target of humoral autoreactivity in myocarditis and rejection. Z Kardiol 1989;78:Suppl 5:95-9.
53. Maisch B, Trostel-Soedei R, Stechemesser E, Berg PA, Kochsick K. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 1982,48.533-45
54. Maisch B Prognostische Determinanten bei Myokarditis und Perimy okardits. Dtsch. Arztebl 1990,87:251-6.
55. Maisch B, Schonian U, Hengstenberg C, et al Immunosuppressive treatment in autoreactive myocarditis: results from a controlled trial. Postgrad Med J 1994;70: Suppl 1:29-34
56. Maisch B, Schonian U, Crombach M, et al Cytomegalovirus associated inflammatory heart muscle disease. Scand J Infect Dis. 1993;Suppl 88 135-48.
57. Manch B,Schonian U, Hufnagel G, Pankuweit S. Enteroviral persistence in myocarditis and dilated cardiomvopathy. Eur Heart J 1997;18;593
58. Maisch B, Pausch R, Hufnagel G, Schonian U. The neglected role of DNA-viruses in chronic mvocarditis and dilated cardiomyopathy. Eur Heart J 1997;18-515.
59. Martin AB, Webber S, Fricker J, et al. Acute myocarditis: Rapid diagnosis in children. Circulation 1994;90-330-9.
60. Mason JW, O'Connell JB, Herskowitz, et al, A clinical mal of immunosuppressive therapy for myocarditis. N Engl J Med 1995,333:269-75.
61. Mason JW, O'Connell, McManus BM Immunosuppressive therapy for myocarditis (author's reply). N Engl J Med 1995,3331714.
62. Mason JW, Billingham ME, Ricci DR. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980,45:1037-44.
63. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Comm 1996;222:678-82.
64. Matsuniori A, Matoba Y, Sasayama S. Dilated Cardiomyopathy associated with Hepatitis C virus infection. Circulation 1995,92:2519-25.
65. Matsumori A, Kawai C. Immunomodulating therapy in experimental myocarditis. Semin Immunopathol 1989; 11:77-88.
66. Matsumori A. Lessons from animal experiments in myocarditis. Herz 1992;17:107-11.
67. Matsumori A, Kawai C An experimental model for congestive heart failure following encephalomyocardicis virus myocarditis in mice Circulation 1982;62:1230-5.
68. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon-alpha A/D in a murine model. J Am Coll Cardiol 1987,9:1320-9.
69. McKenna WJ, Davies MJ. Immunosuppression for mvocarditis (editorial). N Engl J Med 1995;333.312-3.
70. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myctcardiris and acute cardiomyopathy. Circulation 1997;95. 2476-8.
71. Mine M, Miscovic A, Vasiljevic JD, Keserovic N, Pesic M Interferon and thymic horniones in the therapy of human myocarditis and idiopathic dilated cardiomyopathy. Eur Heart J 1995,16:Suppl O 150-7.
72. O'Connell JB, Reap E, Robinson JA The effect of cyclosporine on acute murine coxsackievirus B3 myocarditis. Circulation 1986;73:353-5.
73. Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
74. Packer M, O'Connoer CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in sever chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996,335: 11017-14.
75. Parillo JE, Cunnion RE, Epstein SE, et al A prospective randomized. controlled trial of prednisone for dilated cardiomyopathy N Engl J Med 1989;321-1061-8
76. Richardson D, McKenna W, Bristow M, et al WHO/ ISCF Task Force definition and classification of cardiomyopathies Circulation 1996;93:23-4.
77. Schönian U, Crombach M, Maisch B. Assessment of cytomegalovirus. DNA and protein expression in patients with myocarditis. Clin Immunol Immunopathal 1993,68: 229-33.
78. Schonian U, Crombach M, Maser S, Maisch B. Cytomegalovirus-associated heart muscle disease. Eur Heart J 1995;16 46-9.
79. Schultheiß H-P, Kühl U, Janda I, Schanwell M Strauer BE. Immunosuppressive therapy in myocardits Herz 1992; 17-112-21
80. Schulze K, Becker BF, Schultheiss H-P. Autoimmunity to an intracellular protein: antibodies to the ADP/ATP carner penetrate into myocardial cells and disturb energy metabolism in vivo Circ Res 1991;64:179-92.
81. Schwimmbeck PL, Badorff C, Schultheiss HP, Strauer BE Transfer of human myocarditis into severe combined iimmunodefficiancy mice Circ Res 1994;75: 156-64.
82. Sekiguchi M, Yu ZX, Hasurni M, Hiroe M, Monmoto S, Nishikawa T. Histopathologic and ultrastructural observations of acute and convalescent myocarditis: A serial endomyocardial biopsy study. Heart Vessel 1985;1: Suppl 1.143-53.
83. Shanes JG, Gahli J, Bilingham ME, et al Interobserver variability in the pathological interpretation of endomyocardial biopsy reaulrs. Circulation 1987;75-401-5.
84. Sharaf AR, Narula J, Nicol PD, Southern JF, Khaw BA. Cardiac sarcoplasmic reticulum calcium ATPase. an autoimmune antigen in experimental cardiomyopathy. Circulation 1994;89:1217-28.
85. Stanek G, Klein J, Bitnner R, Glogar D. Isolation of borrelia burgdorfen from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med 1990;322:249-52.
86. Stille Siegener M, Heim A, Figulla HR. Subclassification of dilated cardiomyopathy and Interferon treatment. Eur Heart J 1995,16-Suppl O:147-9.
87. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobuloin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 1995;92: 1604-11
88. The CONSENSUS Trial Study Group Effects of enalapril on mortaliry in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316: 1429-35.
89. Tilles JG, Elson SH, Shaka JA, Abdmann WH, Lemer AM, Finland M. Effects of exercise on coxsackie B-9 myocarditis in adult mice. Proc Soc Exp Biol Med 1964;117:777-82.
90. Towbin JA, Ni J, Demmler G. Evidence for adenovirus as common, cause of myocarditis in children using polymerase chain reaction (PCR). Pediatr Res 1993; 33:27A.
91. Tracy S, Wiegand V, McMarius B, et al. Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis J Am Coll Cardiol 1990;15: 1688-94
92. Tracy S, Hufnagel G, Chapman N. Interesting problems in enteroviral inflammatory heart disease. Herz 1992;17. 79-84.
93. Vignola H, Aonuma K, Swaye PS, et al. Lymphocync myocarditis presenting as unexplained ventricular arrhythmias; diagnostic with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984;4.811-9.
94. Waagstein F, Adrenergic beta-blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Eur Heart J 1995;16:Suppl J:128-32.
95. Wallukat G, Morwinski M, Kowai K, Förster A, Boewer V, Wollenberg A. Autoanribodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization. Eur Heart J 1992;17:Suppl D:178-81.
96. Wang WZ, Matsumon A, Yamada T, et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis A possible mechanism through inhibition of nitnc oxide production Circulation 1997;95:245-51.
97. Weiss L, Mohaved L, Billingham ME, Cleary ML. Detection of coxsackie B3 RNA in myocardial tissues by polymerase chain reaction. Am J Pathol 1991; 138: 497-503.
98. Weller A, Huber S, Herzum M Genetics in viral heart disease. J Mol Genet 1982;27:332-8.
99. WHO/ISCF Task Force (Richardson P, Mckenna W, Bristow M, et al.). Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
100. Woodruff JF, Woodruff JJ Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J Immunol 1974;113:1726-34.
101. Yamada T, Matsumori A, Saasayama S. Therapeutic effect of anti-tumor necrosis factor a antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994;89:846-31.
102. Zee-Cheng CS, Tsai CC, Palmer DC, Codd JE, Pennington DG, Williams GA. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathy congestive cardiomyopathy. J Am Coll Cardiol 1984;3.63-7
103. ZhangS, Kodama M, Hanawa H, Izumi T, Shibata A, Masani F. Effects of cyclosporme, predmsolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-60.